Benzinga · Sep 30, 2026
Chemomab Amends Merger Agreement Ahead Of U.S. Redomiciliation And Scipher Combination
-SEC Filing
CM
NASDAQ · CMMB
Chemomab Therapeutics Ltd.
Healthcare · Biotechnology
$1.00
Up+$0.04 (+4.00%)
Updated Oct 27, 2026, 2:59 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 14.53M
- P/E ratio
- -1.45
- Dividend yield
- 0.00%
- 52-week range
- $1.01 – $3.23
- Volume
- 37.85K
- Avg. volume
- 157.57K
Price performance · CMMB
CMMB price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
CMMB closed at $1.00 after 21 trading sessions, down 39.02% for the selected period.
- Last close
- $1.00
- Period change
- -39.02%
- Period low
- $1.00
- Period high
- $1.64
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $1.10 | $1.10 | $0.9201 | $1.00 | 37.85K |
| Oct 23, 2026 | $1.10 | $1.205 | $1.01 | $1.03 | 26.2K |
| Oct 22, 2026 | $1.15 | $1.24 | $1.01 | $1.08 | 54.8K |
| Oct 21, 2026 | $1.18 | $1.23 | $1.15 | $1.15 | 14.81K |
| Oct 20, 2026 | $1.24 | $1.29 | $1.17 | $1.18 | 64.83K |
| Oct 19, 2026 | $1.25 | $1.26 | $1.17 | $1.17 | 36.62K |
| Oct 16, 2026 | $1.27 | $1.35 | $1.2574 | $1.265 | 9.08K |
| Oct 15, 2026 | $1.29 | $1.355 | $1.25 | $1.29 | 21.53K |
| Oct 14, 2026 | $1.26 | $1.3454 | $1.26 | $1.29 | 25.82K |
| Oct 13, 2026 | $1.37 | $1.41 | $1.24 | $1.24 | 49.76K |
| Oct 12, 2026 | $1.38 | $1.46 | $1.38 | $1.39 | 17.25K |
| Oct 9, 2026 | $1.39 | $1.47 | $1.37 | $1.38 | 12.2K |
| Oct 8, 2026 | $1.40 | $1.44 | $1.36 | $1.39 | 20.6K |
| Oct 7, 2026 | $1.38 | $1.3993 | $1.36 | $1.37 | 10.04K |
| Oct 6, 2026 | $1.5699 | $1.5699 | $1.38 | $1.40 | 25.23K |
| Oct 5, 2026 | $1.43 | $1.49 | $1.39 | $1.41 | 58.7K |
| Oct 2, 2026 | $1.30 | $1.435 | $1.30 | $1.43 | 42.06K |
| Oct 1, 2026 | $1.25 | $1.40 | $1.25 | $1.30 | 195.52K |
| Sep 30, 2026 | $1.62 | $1.665 | $1.051 | $1.19 | 678.26K |
| Sep 29, 2026 | $1.59 | $1.7702 | $1.50 | $1.61 | 437.85K |
| Sep 28, 2026 | $2.20 | $2.22 | $1.61 | $1.64 | 349.77K |
Latest CMMB news
The latest Smart Investors Daily articles mentioning CMMB.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CMMB research
Overview
Company profile and research snapshot.
Company profile
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2025 | Oppenheimer | Outperform | — |
| May 16, 2025 | Oppenheimer | Outperform | — |
| Feb 20, 2025 | Maxim Group | Buy | — |
| Nov 15, 2024 | Oppenheimer | Outperform | — |
| May 13, 2024 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 31, 2026
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference. Dr. Mor’s prerecorded presentation will be webcast and will be available starting on September 11, 2026 at 7:
Benzinga · Aug 19, 2026
CORRECTION: Chemomab Therapeutics Q2 EPADS $(0.27) Misses $(0.15) Estimate
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.15) by 80 percent. This is a 25 percent increase over losses of $(0.36) per share
SeekingAlpha · Jul 9, 2026
Chemomab Therapeutics Ltd. (CMMB) Chemomab Therapeutics Ltd., - M&A Call - Slideshow
2026-07-09. The following slide deck was published by Chemomab Therapeutics Ltd.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
